These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 30201848)
1. Therapeutic Lifestyle Changes Improve HDL Function by Inhibiting Myeloperoxidase-Mediated Oxidation in Patients With Metabolic Syndrome. Mathew AV; Li L; Byun J; Guo Y; Michailidis G; Jaiswal M; Chen YE; Pop-Busui R; Pennathur S Diabetes Care; 2018 Nov; 41(11):2431-2437. PubMed ID: 30201848 [TBL] [Abstract][Full Text] [Related]
2. Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease. Wang G; Mathew AV; Yu H; Li L; He L; Gao W; Liu X; Guo Y; Byun J; Zhang J; Chen YE; Pennathur S PLoS One; 2018; 13(3):e0193782. PubMed ID: 29505607 [TBL] [Abstract][Full Text] [Related]
4. Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-Density Lipoprotein Functionality in Metabolic Syndrome. Khan AA; Mundra PA; Straznicky NE; Nestel PJ; Wong G; Tan R; Huynh K; Ng TW; Mellett NA; Weir JM; Barlow CK; Alshehry ZH; Lambert GW; Kingwell BA; Meikle PJ Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):438-447. PubMed ID: 29284607 [TBL] [Abstract][Full Text] [Related]
5. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Vivekanandan-Giri A; Slocum JL; Byun J; Tang C; Sands RL; Gillespie BW; Heinecke JW; Saran R; Kaplan MJ; Pennathur S Ann Rheum Dis; 2013 Oct; 72(10):1725-31. PubMed ID: 23313808 [TBL] [Abstract][Full Text] [Related]
6. Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels. Hansel B; Bonnefont-Rousselot D; Orsoni A; Bittar R; Giral P; Roussel R; Marre M; Mohammedi K; Bruckert E; Chapman MJ; Kontush A J Clin Lipidol; 2016; 10(5):1172-81. PubMed ID: 27678434 [TBL] [Abstract][Full Text] [Related]
7. A lifestyle intervention with an energy-restricted Mediterranean diet and physical activity enhances HDL function: a substudy of the PREDIMED-Plus randomized controlled trial. Sanllorente A; Soria-Florido MT; Castañer O; Lassale C; Salas-Salvadó J; Martínez-González MÁ; Subirana I; Ros E; Corella D; Estruch R; Tinahones FJ; Hernáez Á; Fitó M Am J Clin Nutr; 2021 Nov; 114(5):1666-1674. PubMed ID: 34582548 [TBL] [Abstract][Full Text] [Related]
8. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Shao B; Tang C; Sinha A; Mayer PS; Davenport GD; Brot N; Oda MN; Zhao XQ; Heinecke JW Circ Res; 2014 May; 114(11):1733-42. PubMed ID: 24647144 [TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. Zheng L; Nukuna B; Brennan ML; Sun M; Goormastic M; Settle M; Schmitt D; Fu X; Thomson L; Fox PL; Ischiropoulos H; Smith JD; Kinter M; Hazen SL J Clin Invest; 2004 Aug; 114(4):529-41. PubMed ID: 15314690 [TBL] [Abstract][Full Text] [Related]
10. Structured lifestyle intervention in patients with the metabolic syndrome mitigates oxidative stress but fails to improve measures of cardiovascular autonomic neuropathy. Pennathur S; Jaiswal M; Vivekanandan-Giri A; White EA; Ang L; Raffel DM; Rubenfire M; Pop-Busui R J Diabetes Complications; 2017 Sep; 31(9):1437-1443. PubMed ID: 28709739 [TBL] [Abstract][Full Text] [Related]
12. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. Shao B; Pennathur S; Heinecke JW J Biol Chem; 2012 Feb; 287(9):6375-86. PubMed ID: 22219194 [TBL] [Abstract][Full Text] [Related]
13. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. Shao B; Heinecke JW J Proteomics; 2011 Oct; 74(11):2289-99. PubMed ID: 21501700 [TBL] [Abstract][Full Text] [Related]
14. Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia. Boyer M; Mitchell PL; Poirier P; Alméras N; Tremblay A; Bergeron J; Després JP; Arsenault BJ Am J Physiol Endocrinol Metab; 2018 Oct; 315(4):E460-E468. PubMed ID: 29870675 [TBL] [Abstract][Full Text] [Related]
15. Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study). Akinmolayemi O; Saldanha S; Joshi PH; Deodhar S; Ayers CR; Neeland IJ; Rohatgi A PLoS One; 2021; 16(9):e0257574. PubMed ID: 34547056 [TBL] [Abstract][Full Text] [Related]
16. Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study. Annema W; Dikkers A; de Boer JF; van Greevenbroek MMJ; van der Kallen CJH; Schalkwijk CG; Stehouwer CDA; Dullaart RPF; Tietge UJF Sci Rep; 2016 Jun; 6():27367. PubMed ID: 27270665 [TBL] [Abstract][Full Text] [Related]